Bonus Biogroup is a clinical-stage biotech company based in Haifa, Israel, developing two cell therapy and tissue engineering products. BonoFill is a personalized, autologous bone graft for large bone defects that cannot heal on their own. The process involves extracting a small fat tissue sample from the patient, isolating and growing mesenchymal stromal cells (MSCs) on a 3D mineral scaffold in a proprietary bioreactor, and transplanting the resulting live bone tissue into the defect. BonoFill is designed to replace autografting — the current standard of care — which requires harvesting bone from the patient's own body and carries significant complications. MesenCure is an allogeneic, donor-derived MSC therapy targeting inflammation and tissue damage, initially aimed at treating Acute Respiratory Distress Syndrome (ARDS). Unlike supportive treatments like mechanical ventilation, MesenCure is designed to target the underlying inflammation and lung damage directly. Bonus Biogroup has generated no revenue to date. If approved, BonoFill would be manufactured on a per-patient basis, while MesenCure would be produced at scale from banked donor cell lines, with one donor bank potentially yielding enough material for up to 70,000 patients. Bonus Biogroup plans to commercialize in the U.S. through a third-party distribution partner rather than building its own sales force. Both products are advancing toward Phase III trials in the U.S., with regulatory submissions targeted around 2028.